Drugs / Nadolol
Regulatory milestones approvals, filings & regulatory actions · 3 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (2) | US (FDA) | CORGARD | — | 1984-11-16 – 1986-10-28 | fda.gov ↗ |
| Approved | US (FDA) | CORGARD | — | 1979-12-10 | fda.gov ↗ |
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00960245 | Jul 1994 | hypertensive disorder, migraine disorder | Sandoz | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00670267 | Jan 2007 → May 2009 | asthma | Invion, Inc. | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT04739423 | Jun 2021 → Jul 2022 | Lewy body dementia, Parkinson disease, REM sleep behavior disorder | CuraSen Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01825122 | Mar 2014 → Jun 2015 | — | Invion, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01804218 | Mar 2013 → May 2016 | chronic asthma | Invion, Inc. | Unknown | No outcome recorded |
| Phase 2 | NCT01010308 | Nov 2009 → May 2011 | hemangioma | The Hospital for Sick Children | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT05585125 | Feb 2024 → Jul 2026 overdue | diastolic heart failure | Weill Medical College of Cornell University | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT05019027 | Jan 2024 → Mar 2026 overdue | amyloidosis, heart disorder | Weill Medical College of Cornell University | Enrolling by invitation | No outcome recorded |
Also used as a comparator or background therapy in 15 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06643221 Comparator | Jan 2018 → May 2031 expected | leukemia, lymphoma | University of Arizona | Recruiting | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT00648297 Comparator | Aug 2006 | — | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1 | NCT00647660 Comparator | Jul → Aug 2006 | — | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02505971 Comparator | Sep 2015 → Apr 2020 | hemangioma | The Hospital for Sick Children | Completed | No outcome recorded |
| Phase 48 trials | ||||||
| Phase 4 | NCT04757584 Comparator | Apr 2021 → Apr 2023 | diastolic heart failure | Weill Medical College of Cornell University | Completed | No outcome recorded |
| Phase 4 | NCT04767061 Comparator | Apr 2021 → Apr 2022 | diastolic heart failure | Weill Medical College of Cornell University | Completed | No outcome recorded |
| Phase 4 | NCT07405229 Comparator | May 2018 → Dec 2032 expected | cardiac arrest, ventricular fibrillation | Bo Gregers Winkel | Recruiting | No outcome recorded |
| Phase 4 | NCT00567216 Comparator | Apr 2007 → Jul 2010 | hepatocellular carcinoma, varicose disease | Taipei Veterans General Hospital, Taiwan | Unknown | No outcome recorded |
| Phase 4 | NCT01103154 Comparator | Mar 2005 → Jan 2010 | esophageal varices with bleeding | E-DA Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00921349 Background | Dec 2004 → May 2009 | cirrhosis of liver, esophageal varices with bleeding | National Science and Technology Council, Taiwan | Completed | No outcome recorded |
| Phase 4 | NCT00910689 Comparator | Jul 2001 → Nov 2005 | migraine disorder | Ohio University | Completed | No outcome recorded |
| Phase 4 | NCT00450164 Background | Nov 2000 → Jun 2004 | cirrhosis of liver, portal hypertension | Sant Pau Research Institute | Completed | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT07168395 Comparator | Oct 2026 → Nov 2027 expected | — | University of California, Los Angeles | Not yet recruiting | No outcome recorded |
| — | NCT01117454 Background | Dec 2011 → Dec 2015 | catecholaminergic polymorphic ventricular tachycardia | Vanderbilt University Medical Center | Completed | No outcome recorded |
| — | NCT00684489 Comparator | Sep 2003 → Mar 2005 | essential hypertension | Medical University of South Carolina | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 23 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nadolol | “The betablocker given to the patient will be prioritized: 1) A non-selective betablocker: Propranolol Retard 80 mg daily or Nadolol 40 mg daily OR 2) A selective betablocker:...” NCT07405229 ↗22“Other names: acebutolol, atenolol, betaxolol, bisoprolol, carvedilol, labetalol, metoprolol, metoprolol succinate, metoprolol tartrate, nadolol, nebivolol, propranolol,...” NCT05585125 ↗ “Other Names: * acebutolol * atenolol * betaxolol * bisoprolol * carvedilol * labetalol * metoprolol succinate * metoprolol tartrate * nadolol * nebivolol * penbutolol *...” NCT05019027 ↗ “Standard therapy with beta-blocker (nadolol, atenolol, metoprolol, or propranolol) continues throughout the trial.” NCT01117454 ↗ “bisoprolol, metoprolol, nadolol, propranolol, timolol” NCT00684489 ↗ “These may include propranolol, nadolol, and timolol.” NCT07168395 ↗ “nadolol” NCT04767061 ↗ “nadolol” NCT04757584 ↗ |
| Known as | CST-107 | “clenbuterol (CST-103) and matching placebo orange capsules; nadolol (CST-107) and matching placebo white capsules” NCT04739423 ↗ |
| Action | Inhibit | “a drug (beta blocker) that blocks stress hormones like adrenaline” NCT06643221 ↗ |
| Route | Oral | “single, oral 80 mg/5 mg (1 x 80 mg/5 mg) dose administered under fasting conditions” NCT00647660 ↗ |